Age at diagnosis is an important prognostic factor in Philadelphia‐negative Myeloproliferative Neoplasms

Merav Barzilai and others recently conducted a retrospective study on 109 patients with Philadelphia-negative Myeloproliferative Neoplasms (MPNs) aged between 18 and 45 years (1). The authors conclude that the risk of death and progression to myelofibrosis and leukemia in this population is similar to that found in the counterpart over the age of 45 years. Our experience does not confirm Barzilai's data. This article is protected by copyright. All rights reserved.

[1]  N. Lavi,et al.  Characteristics and outcomes of young adults with Philadelphia‐negative myeloproliferative neoplasms , 2019, European journal of haematology.

[2]  A. Tefferi,et al.  Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger , 2018, American journal of hematology.

[3]  T. Barbui,et al.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion , 2018, Blood Cancer Journal.

[4]  A. Tefferi,et al.  Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 Mayo clinic patients , 2016, American journal of hematology.

[5]  T. Barbui,et al.  Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). , 2012, Blood.

[6]  M. Griesshammer,et al.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[9]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.